Understanding how cancer metabolism affects chemotherapy resistance in pancreatic cancer
Official title: Cancer and stromal metabolic reprogramming drives chemotherapy resistance in human models of pancreatic cancer
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-11073933 · Data updated 2026-11-12
This study is looking into why pancreatic cancer doesn't respond well to regular chemotherapy and hopes to find new ways to make these treatments work better for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | September 20, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $161,750 |
| NIH project number | 3U54CA274329-03S1 |
| Project ID | NIH-11073933 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic cancer who are undergoing or have undergone chemotherapy.
✕Less likely to help
Patients with pancreatic cancer who are not receiving chemotherapy or those with very early-stage disease may not benefit from this research.
What this research studies
This research investigates the reasons behind the poor response of pancreatic cancer to standard chemotherapy treatments. It focuses on how changes in the metabolism and signaling of both cancer cells and surrounding supportive cells (stroma) contribute to the development of resistance to these therapies. By studying these interactions, the research aims to identify new therapeutic strategies that could enhance the effectiveness of existing treatments. Patients may benefit from insights that lead to improved treatment options tailored to their specific cancer characteristics.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving patient outcomes and survival rates.
How similar studies have gone: Previous research has shown promise in understanding metabolic changes in cancer cells and their role in treatment resistance, suggesting that this approach could yield significant insights.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Singh, Pankaj Kumar — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Singh, Pankaj Kumar
Related research
Other NIH-funded projects on the same topics.
-
Combination therapy with a T-cell engager and chemotherapy for pancreatic cancer
A new treatment approach combines a T-cell engaging antibody with standard chemotherapy to help treat pancreatic cancer, aiming to slow tumor growth and improve outcomes.
-
Tumor-targeted delivery of radio/chemotherapy for pancreatic cancer
A new treatment approach combines a targeted drug delivery system with a radioactive payload to attack pancreatic cancer cells that have mutant KRAS.
-
MRI-guided chemotherapy for borderline-resectable pancreatic cancer
This project uses special MRI scans to help pick the best pre-surgery chemotherapy for people whose pancreatic tumor is touching nearby vessels but might be removable after treatment.
-
A targeted therapy plan using endoscopic heat treatment plus chemotherapy for pancreatic cancer
A patient-focused plan tests using a special endoscopic heat treatment together with chemotherapy to treat pancreatic cancer.
-
Combining Chemotherapy with Targeted Ablation for Pancreatic Cancer
This research is testing a new way to treat pancreatic cancer by combining standard chemotherapy with a targeted heat treatment called radiofrequency ablation.
-
Combining chemotherapy with a new treatment method for pancreatic cancer
This study is looking at how well combining regular chemotherapy with a special treatment called endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) works for people with pancreatic cancer, hoping to boost their immune response and improve their chances of recovery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.